Bladder transitional cell carcinoma+2
Not recruitingStudy Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer
Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer
- Disease:Bladder transitional cell carcinomaTransitional cell cancer of the renal pelvis and ureter+1
- Substances:DocetaxelPaclitaxel+2
France- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Gilead Sciences Inc.










